In 2017, the authors showed that CPT1A isoform is abundant in high-grade PCa compared to benign tissues, and they demonstrated a synergistic effect in combining CPT-1A inhibitors with anti-androgen therapy. The gene discussed is CPT1A; the disease is posterior cortical atrophy.